相关实验视频

Updated: Jun 21, 2025

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

直接作用的抗病毒药物用于RSV治疗,一个审查

Brecht Bonneux¹, Edgar Jacoby², Martina Ceconi³

¹Laboratory for Microbiology, Parasitology and Hygiene, University of Antwerp, Universiteitsbaan 1, 2610, Wilrijk, Belgium; Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium.

Antiviral research

|July 7, 2024

概括

针对呼吸道同胞性病毒 (RSV) 的新型抗病毒治疗正在开发中,重点是病毒进入和复制. 了解耐药机制是推进有效RSV疗法的关键.

科学领域:

病毒学病毒学
传染性疾病传染性疾病
药物发现药物发现药物发现

背景情况:

呼吸道同胞性病毒 (RSV) 在脆弱人群中引起显著的呼吸道疾病.
目前对RSV的治疗选择有限,只有一个批准的抗病毒药物 (利巴维林).
现有的疫苗和单克隆抗体专注于预防,而不是直接治疗.

研究的目的:

审查目前直接针对RSV的治疗方法.
确定用于抗病毒药物开发的关键病毒过程.
分析RSV抗病毒研究的进展和挑战.

主要方法:

关于RSV抗病毒治疗的科学文献的综述.
病毒点的分析:融合蛋白和聚合酶复合体.
检查临床开发状态和程序停止的原因.

主要成果:

确定了两个主要的病毒标:融合和聚合酶复合体.
抗性突变为抑制剂结合口袋和作用机制提供信息.
临床试验中的RSV抗病毒药物数量有限 (1期III,3期II,2期I).

结论:

针对RSV融合和聚合酶提供了有前途的抗病毒策略.
了解耐药性对于开发有效的抑制剂至关重要.
从停止的药物开发计划中吸取的教训可以提高RSV治疗的未来成功率.

关键词:

临床成功临床成功这是一种直接的抗病毒药物.核聚变技术是可以实现的.聚合酶是一种聚合酶.呼吸系统同胞性病毒治疗方法治疗方法

更多相关视频

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

相关概念视频

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...